Rodríguez-Lago Iago, Aguirre Urko, Cabriada Jose Luis, Ungaro Ryan C, Colombel Jean-Frédéric, Barreiro-de Acosta Manuel
Gastroenterology Department, Hospital Universitario de Galdakao, Biobizkaia Health Research Institute, Galdakao, Spain.
Research Unit, Hospital Universitario de Galdakao, REDISSEC, Galdakao, Spain.
Am J Gastroenterol. 2024 Dec 30;120(6):1391-1394. doi: 10.14309/ajg.0000000000003275.
This study investigates whether subclinical inflammation in asymptomatic patients with inflammatory bowel disease (IBD) leads to increased medication use. In a multicenter, retrospective analysis of patients diagnosed with incidental ulcerative colitis or Crohn's disease during colorectal cancer screening (2010-2021), medication use was compared with symptomatic patients and healthy non-IBD controls. Asymptomatic patients showed a higher use of cardiovascular, antiparasitic, musculoskeletal, respiratory, and sensory organ medications up to 5 years before diagnosis. This trend suggests that a systemic inflammatory process occurs years before clinical onset of IBD, suggesting the potential for earlier diagnosis and intervention.
本研究调查了无症状炎症性肠病（IBD）患者的亚临床炎症是否会导致用药增加。在一项对2010年至2021年期间在结直肠癌筛查中被诊断为偶发性溃疡性结肠炎或克罗恩病患者的多中心回顾性分析中，将用药情况与有症状患者及健康非IBD对照进行了比较。无症状患者在诊断前长达5年的时间里，心血管、抗寄生虫、肌肉骨骼、呼吸及感觉器官用药的使用量更高。这一趋势表明，IBD临床发病前数年就已发生全身性炎症过程，提示有早期诊断和干预的可能性。
